2023
Presentation Date:
Format: Fireside chat
Relmada management will also be available for one-one-one investor meetings during the conference. Please contact your Jefferies representative if you would like to schedule a meeting.
The webcast can be accessed via the Investors section of the Relmada website at https://www.relmada.com/for-investors. An archived replay will be available for 90 days following the conclusion of the event.
About REL-1017
REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD). The ongoing Reliance Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment.
About
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as 'expects,' 'anticipates,' 'believes,' 'will,' 'will likely result,' 'will continue,' 'plans to,' 'potential,' 'promising,' and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of Reliance trial results to demonstrate clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, and the other risk factors described under the heading 'Risk Factors' set forth in the Company's reports filed with the
Contact:
Email: Tim@LifeSciAdvisors.com
(C) 2023 Electronic News Publishing, source